Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

First Circuit Adopts “But For” AKS Standard, Leaving Third Circuit Alone in Causal-Link Standard

By Ryan B. Marcus, Brenna M. Molinare, Craig B. Bleifer, Michael J. Podberesky, Allyson M. Maur, Zoë Smith & Timothy Fry on March 4, 2025
Email this postTweet this postLike this postShare this post on LinkedIn

On Feb. 18, 2025, the U.S. Court of Appeals for the First Circuit adopted the “but for” causality standard for violations of the federal Anti-Kickback Statute (AKS) that give rise to violations of the federal False Claims Act (FCA). In United States v. Regeneron, the First Circuit held that for a violation of the AKS to constitute a false claim subject to the FCA, the government must demonstrate that the illicit kickback was the “but for” cause of a submitted claim.

This holding ended an intra-circuit split between two district court opinions including the lower court’s ruling in this case and aligns the First Circuit with the Sixth and Eighth circuits’ interpretations. The holding leaves the Third Circuit as the only circuit allowing the government to rely on a “causal link” standard between an AKS violation and the submission of a false claim subject to the FCA.

Circuit Split

The Patient Protection and Affordable Care Act (ACA) amended the AKS in 2010 to add a provision stating that “a claim that includes items or services resulting from a violation of [the AKS] constitutes a false or fraudulent claim for purposes of” the FCA. A question arose as to what “resulting from” means as a causality standard for AKS-based FCA cases. In 2018, the Third Circuit held in DiFiore v. CSL Behring that it is sufficient for the government to show only that the kickback payment was made in the chain of events leading to the false claim. The Third Circuit is the only circuit to apply this standard.

The First Circuit joins the Sixth and Eighth circuits in holding that “resulting from” means a “but for” connection. The government must show that a claim submitted to a federal healthcare program would not have been submitted but for the payment of a kickback specifically related to that claim. This standard is more rigorous and may potentially bar relators and the government from bringing claims under the FCA.

First Circuit Holding in Regeneron

In United States v. Regeneron, the government alleged that Regeneron Pharmaceuticals directed donations to the Chronic Disease Fund, a charitable organization, to help cover patient co-payments for the Regeneron drug Eylea. The government alleged that Regeneron’s donations constituted a knowing inducement of the prescription of Eylea in violation of the AKS. The government claimed that any time a Medicare beneficiary received the benefit of co-pay assistance from the Chronic Disease Fund to purchase Eylea and a claim for the drug was submitted to Medicare for payment, the claim was false in violation of the FCA.

The First Circuit directly addressed the district courts’ interpretations of “resulting from” in the AKS, resolving two district court opinions that conflicted within the circuit. The court noted that statutes that use “resulting from” usually impose a requirement of actual causality. Thus, without textual or contextual indications that support an alternative approach, a “but for” meaning was the appropriate standard under the AKS.

The First Circuit found no contextual reasons for the court to depart from the “but for” standard. It rejected the government’s arguments that the statutory amendment in 2010 built on the AKS scheme and denied the imposition of criminal liability when such standard did not exist. The First Circuit reasoned that Congress could establish new pathways for liability under AKS without connecting to the previous scheme. The First Circuit found that the AKS’ statutory history does not indicate any intention to depart from a direct causation standard because there was no convincing history to demonstrate that Congress had different intentions. Finally, the court rejected the contention that a “but for” standard would create an impossible standard since the 2010 amendment created a pathway that does not require proof of a false certification, and held that the “but for” standard is not more strenuous than other elements under the FCA.

Split Moving Forward

The First Circuit’s holding sets a clear split between the First, Sixth and Eighth circuits and the Third Circuit in the interpretation of the “resulting from” language that ties AKS violations to the FCA. The “but for” standard in the First, Sixth and Eighth circuits creates a more stringent standard for relators and the government, requiring complainants to demonstrate the alleged false claim would not have been submitted but for a violation of the AKS. It remains unclear if or when the U.S. Supreme Court will have the opportunity to resolve the circuit split, after having previously denied certiorari to the Sixth Circuit’s decision in U.S. ex rel. Martin v. Hathaway in 2023. Beyond potential judicial review, there also could be legislative action amending the FCA to clarify the AKS causation standard.

McGuireWoods will continue to monitor developments in this circuit split.

Photo of Ryan B. Marcus Ryan B. Marcus

Ryan maintains a national practice representing health care-focused private equity funds and their portfolio companies, independent sponsors investing in health care, and hospitals and health systems in a wide range of transactional and regulatory matters. Ryan leverages his broad experience in transactional and…

Ryan maintains a national practice representing health care-focused private equity funds and their portfolio companies, independent sponsors investing in health care, and hospitals and health systems in a wide range of transactional and regulatory matters. Ryan leverages his broad experience in transactional and regulatory matters to provide solutions to complex health care matters arising in traditional mergers and acquisitions, joint ventures, and other complex collaborations.

Read more about Ryan B. MarcusEmail
Show more Show less
Photo of Brenna M. Molinare Brenna M. Molinare

Brenna focuses her practice on the healthcare industry, advising clients on transactional, regulatory, and compliance matters.

Read more about Brenna M. MolinareEmail
Photo of Craig B. Bleifer Craig B. Bleifer

Craig is a seasoned healthcare executive, previously serving as general counsel for two major pharmaceutical companies, Novo Nordisk and Daiichi Sankyo. With over 30 years as a corporate and life sciences lawyer, he provides counsel on legal, compliance, policy, and regulatory issues related…

Craig is a seasoned healthcare executive, previously serving as general counsel for two major pharmaceutical companies, Novo Nordisk and Daiichi Sankyo. With over 30 years as a corporate and life sciences lawyer, he provides counsel on legal, compliance, policy, and regulatory issues related to healthcare products and businesses. He provides strategic advice based on his practical real-world experiences, spanning discovery to commercialization.

Read more about Craig B. BleiferEmail
Show more Show less
Photo of Michael J. Podberesky Michael J. Podberesky

Michael Podberesky, a former federal prosecutor in the U.S. Department of Justice’s Civil Fraud Section, is a partner in the firm’s nationally recognized Government Investigations and White Collar Litigation Department and co-leader of the firm’s Healthcare Litigation and Enforcement Practice Group. Employing his…

Michael Podberesky, a former federal prosecutor in the U.S. Department of Justice’s Civil Fraud Section, is a partner in the firm’s nationally recognized Government Investigations and White Collar Litigation Department and co-leader of the firm’s Healthcare Litigation and Enforcement Practice Group. Employing his extensive experience with False Claims Act cases in the healthcare and defense sectors, Michael represents clients confronting high-stakes government investigations and litigation arising from allegations of healthcare and procurement fraud and also counsels clients regarding compliance issues.

Read more about Michael J. PodbereskyEmail
Show more Show less
Photo of Allyson M. Maur Allyson M. Maur

Allyson advises on regulatory issues affecting diagnostics developers, biopharma manufacturers, and clinical laboratories, including CLIA/CLEP and FDA regulatory advice, MLR and MRC review of marketing and promotional materials, clinical studies, global data privacy issues, ethics & compliance, commercial contracting, commercial litigation and more.

Read more about Allyson M. MaurEmail
Photo of Zoë Smith Zoë Smith

Zoë brings both her legal and engineering experience to client matters as member of the Environmental and Mass Torts litigation team. She focuses her practice on matters involving mass torts, products liability, and contract disputes. Zoë worked as an industrial engineer at a…

Zoë brings both her legal and engineering experience to client matters as member of the Environmental and Mass Torts litigation team. She focuses her practice on matters involving mass torts, products liability, and contract disputes. Zoë worked as an industrial engineer at a Fortune 500 aerospace and defense company prior to joining McGuireWoods, giving her unique insight into the day-to-day challenges businesses face.

Read more about Zoë SmithEmail
Show more Show less
Photo of Timothy Fry Timothy Fry

Tim resolves clients’ thorny compliance and regulatory issues that make or break healthcare transactions and operations. He delivers practical, business-oriented solutions that clear obstacles, close deals, and protect enterprise value.

Read more about Timothy FryEmail
  • Posted in:
    Business and Commercial
  • Blog:
    The FCA Insider
  • Organization:
    McGuireWoods LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo